BioSpace News Archive

Primary composite first and total major adverse cardiovascular event (MACE) reductions of 23% each shown with VASCEPA in prespecified tertiary and post hoc exploratory analyses of the subgroup of people with diabetes

Designation follows recent announcement on development of first companion diagnostic using the Oncomine Precision Assay on the new Ion Torrent Genexus System

OTC Markets Group Inc., operator of financial markets for 10,000 U.S. and global securities, announced Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, has qualified to trade on the OTCQX® Best Market.

Preclinical data for Sanofi’s investigational compounds in breast, lung, multiple myeloma and other cancers will be featured at the American Academy of Cancer Research Virtual Annual Meeting II on June 22-24.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to NeoImmuneTech’s NT-I7, the only clinical-stage long-acting human IL-7, for the treatment of Progressive Multifocal Leukoencephalopathy.

Abiomed, maker of the Impella heart pump, announced it has appointed Charles Simonton, M.D., as vice president and chief medical officer.

Augmented Reality Surgical Image Guidance Pioneer Announces $15 Million Round Built on Leadership, Ingenuity and Innovation of U.S. Staff

The long-term brain health supplement developed in partnership with the University of Oxford

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received FDA 510(k) clearance to market and sell Venus Epileve

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the filing of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to begin a Phase 1/2a clinical study of GEN-011 in a range of tumor types, with a focus on patients who have failed standard-of-care checkpoint inhibitor therapy.